Europe Stem Cell Assay Market

Europe Stem Cell Assay Market Size (2022 to 2027):

The size of the Europe Stem Cell Assay Market has been calculated at USD 242.51 Million in 2022. This value is further forecasted to be at a CAGR of 19.3% and worth USD 586.05 Million by 2027.

The increasing adoption of advanced technologies and growing expenditure towards the stem cell assay market are majorly impelling the market growth. The increase in patient pool, mainly due to increasing cancer and diabetes incidence and rising investments in stem cell assay therapies, further increases the market demand. Moreover, growing acceptance for clinical trials for stem cell-based therapy, the progression of novel remedies, and less regulatory frameworks are estimated to provide new opportunities for the stem cell-based assay market during the region growth in the assessment period.

Strict government policies and high costs for the maintenance and installation limit the stem cell assay market growth in Europe. Lack of knowledge due to less training programs is likely to hinder the market growth.

This research report on the Europe Stem Cell Assay Market has been segmented and sub-segmented into the following categories:

By Assay Type: 

• Cell Viability & Toxicity Assays
• Purification Assays
• Differentiation Assays
• Function Assays
• Identification Assays
• Proliferation Assays
• Cell Apoptosis Assays

By Kits: 

• Adult Stem Cell Kits
• Human Embryonic Stem Cell Kits

By Application: 

• Regenerative Medicine
• Therapy Development
• Drug Discovery and Development
• Clinical Research

By End User: 

• Research Institutes
• Industry Research

By Country: 

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Based on the region, Germany leads the market in this region due to the increasing adoption of stem cell-based research. The rising elder people population, growing chronic diseases, accelerating investments in research and development activities are surging the market demand. Germany is ruling the stem cell assay market in the Europe region. The introduction of reimbursement policies by the government is leveling up the need of the market. The rising number of people with cancer and cardiovascular diseases is likely to propel the market's growth rate in Germany. The huge patient count and increasing acceptance of novel technologies for diseases like cancer, diabetes, and many more, and a surge in government are significant factors for the market to grow in the UK. 

Promising Companies dominating the Europe Stem Cell Assay Market Profiled in the Report are Thermo Fisher Scientific Inc., Bio-Techne Corporation, Stem cell Technologies Inc., Merck KGaA, Promega Corporation, GE Healthcare, Bio-Rad Laboratories, Inc., Cellular Dynamics International Inc., Hemogenix, and Cell Biolabs Inc.